Abbvie Selloff exaggerated, stocks remain undervalued: BMO
AbbVie’s (ABBV) – Get the report from AbbVie, Inc. The sale was overstated after a September 1 setback for its flagship immunology drug Rinvoq, and the stock remains undervalued, according to BMO analyst Gary Nachman.
It has an outperformance rating and a price target of $ 133. The stock recently traded at $ 106.61, down 0.81%, and has fallen 12% since Aug.31.
On September 1, the Food and Drug Administration mandated new cardiac and cancer safety warnings for Rinvoq and the JAK inhibitor class of drugs from other companies.
âDoctors agreed that Rinvoq is still likely to be approved for atopic dermatitis (AD), given its overall risk / benefit ratio,â Nachman said. âEven with limited use, this could still be a solid opportunity. “
Thus, âour sensitivity analysis to Rinvoq’s already conservative forecast suggests that the sale has been exaggerated,â he said.
Looking at the company as a whole, “ABBV is well positioned to successfully manage Humira’s loss of exclusivity in the United States from January 2023, with sufficiently cautious investors and reasonably low expectations,” Nachman said. .
âABBV is performing very well with its main growth drivers, particularly the strong trends Skyrizi and Rinvoq. Its acquisition of Allergan in May 2020 significantly reduced its focus in Humira.
Morningstar analyst Damien Conover wasn’t overly concerned with the FDA news either. This puts âmoderate pressureâ on Rinvoq, who is estimated to have 6% of AbbVie’s sales in 2023, he said. But that doesn’t affect its fair value estimate of $ 108 for the stock or its narrow moat rating.
AbbVie is a stake in Jim Cramer’s Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells ABBV? Learn more now.